Malmö, Sweden

Monika Semmrich

USPTO Granted Patents = 4 

Average Co-Inventor Count = 5.5

ph-index = 1


Company Filing History:


Years Active: 2022-2025

Loading Chart...
4 patents (USPTO):Explore Patents

Title: Monika Semmrich: Innovator in Antibody Research

Introduction

Monika Semmrich is a prominent inventor based in Malmö, Sweden. She has made significant contributions to the field of antibody research, particularly in the development of novel therapeutic antibodies. With a total of three patents to her name, her work is paving the way for advancements in cancer treatment and infectious diseases.

Latest Patents

Monika's latest patents include groundbreaking innovations such as antagonistic anti-TNFR2 antibodies. These novel antibody molecules specifically bind to TNFR2 on target cells, effectively blocking TNF-α binding and TNFR2 signaling. This mechanism holds promise for treating cancer and infections caused by intracellular pathogens. Another significant patent involves antibodies and nucleotide sequences that describe anti-CTLA-4 antibody molecules. These molecules are designed to deplete Treg cells more effectively than existing treatments, such as ipilimumab, and have potential applications in treating solid tumors.

Career Highlights

Monika Semmrich is currently associated with Bioinvent International AB, where she continues her research and development efforts. Her work has garnered attention in the scientific community, and her patents reflect her innovative approach to solving complex medical challenges.

Collaborations

Monika collaborates with talented individuals such as Ingrid Teige and Linda Mårtensson, contributing to a dynamic research environment that fosters innovation and discovery.

Conclusion

Monika Semmrich's contributions to antibody research are noteworthy and have the potential to impact the treatment of various diseases significantly. Her innovative spirit and dedication to science continue to inspire advancements in the field.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…